|Dr. Jerzy Muchnicki||Interim CEO & Exec. Director||153.11k||N/A||1957|
|Mr. Phillip Hains C.A., M.B.A., B Bus, CA, MBA||Chief Financial Officer||N/A||N/A||1961|
|Mr. Stanley Sack||Chief Operating Officer||318.28k||N/A||1964|
|Dr. Richard Allman||Scientific Director||188.21k||N/A||1960|
|Mr. Paul Keith Mathieson Viney B. Bus, FCPA, FGIA, FCI||Consultant||N/A||N/A||N/A|
|Mr. Justyn Stedwell||Company Sec.||N/A||N/A||1981|
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage patient's health in Australia and the United States. It engages in the development of various cancer risk assessment tests under the GeneType name. The company's lead products are GeneType for breast cancer for non-hereditary breast cancer, and GeneType for colorectal cancer. It also offers BREVAGenplus tests. The company sells its products through online health platform. It has research and collaboration agreements with the University of Melbourne, the Translational Genomics Research Institute, Memorial Sloan Kettering, the Ohio State University, and Harvard Nurses' Health Study. Genetic Technologies Limited was incorporated in 1987 and is based in Fitzroy, Australia.
Genetic Technologies Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.